MLTX
MoonLake Immunotherapeutics NASDAQ Listed Oct 20, 2020$22.16
Pre-mkt
$20.91
-5.64%
Mkt Cap $1.4B
52w Low $6.25
28.5% of range
52w High $61.99
50d MA $17.95
200d MA $18.63
P/E (TTM)
-5.7x
EV/EBITDA
—
P/B
4.7x
Debt/Equity
0.2x
ROE
-74.7%
P/FCF
-7.3x
RSI (14)
70.10
ATR (14)
$1.12
Beta
1.19
50d MA
$17.95
200d MA
$18.63
Avg Volume
996.3K
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Dorfstrasse 29 · Zug, V8 6300 · CH
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | -0.92 | -0.92 | +0.0% | 18.22 | -1.5% | -3.0% | -1.0% | +1.0% | +0.1% | +2.5% | — |
| Nov 5, 2025 | AMC | -0.89 | -1.10 | -23.6% | 10.59 | +0.4% | -2.8% | +3.3% | +1.8% | +8.6% | +8.7% | — |
| Aug 5, 2025 | AMC | -0.73 | -0.87 | -19.2% | 53.41 | -0.2% | -1.2% | -1.6% | +1.0% | +1.9% | +2.7% | — |
| May 12, 2025 | AMC | -0.76 | -0.63 | +17.1% | 40.18 | +1.0% | -4.1% | -4.0% | +1.8% | -0.1% | +4.2% | — |
| Feb 26, 2025 | AMC | -0.53 | -0.72 | -35.8% | 42.37 | -1.0% | -1.4% | -0.0% | -4.9% | +1.5% | -0.8% | — |
| Nov 7, 2024 | AMC | -0.44 | -0.56 | -27.3% | 50.67 | -0.4% | +2.2% | +4.1% | -3.7% | -1.6% | +2.8% | — |
| Aug 7, 2024 | AMC | -0.28 | -0.39 | -39.3% | 43.06 | +0.4% | +6.9% | -3.9% | +2.4% | +0.0% | +3.7% | — |
| May 7, 2024 | AMC | -0.21 | -0.22 | -4.8% | 43.66 | +0.7% | -2.4% | -1.5% | -2.5% | +1.9% | -2.3% | — |
| Feb 29, 2024 | AMC | -0.21 | -0.12 | +42.9% | 48.24 | +2.8% | +5.6% | -4.0% | -1.6% | -6.0% | +0.8% | — |
| Nov 14, 2023 | AMC | -0.22 | -0.18 | +18.2% | 37.40 | +0.3% | +5.0% | +2.6% | +6.1% | -0.2% | +0.5% | — |
| Aug 10, 2023 | AMC | -0.25 | -0.23 | +8.0% | 54.53 | -0.2% | +3.0% | +1.2% | -1.0% | +2.0% | -2.1% | — |
| May 12, 2023 | AMC | -0.28 | -0.23 | +17.9% | 27.72 | +0.9% | -3.5% | +0.7% | +4.5% | -0.2% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | BTIG | Maintains | Buy → Buy | — | $17.32 | $17.26 | -0.3% | -2.3% | +10.1% | -11.4% | +5.1% | -2.2% |
| Mar 23 | Wolfe Research | Upgrade | Underperform → Outperform | — | $16.27 | $16.99 | +4.4% | +3.7% | -0.9% | +7.8% | -1.5% | -2.4% |
| Mar 19 | Rothschild & Co | Upgrade | Neutral → Buy | — | $16.23 | $17.20 | +6.0% | +2.8% | -2.5% | +3.7% | -0.9% | +7.8% |
| Mar 11 | Clear Street | Maintains | Buy → Buy | — | $18.34 | $18.76 | +2.3% | -2.7% | -4.5% | +0.6% | -2.3% | +0.2% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.51 | $17.15 | -2.1% | +1.0% | +0.1% | +2.5% | -0.7% | +0.7% |
| Mar 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $17.51 | $17.15 | -2.1% | +1.0% | +0.1% | +2.5% | -0.7% | +0.7% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $18.22 | $17.94 | -1.5% | -3.0% | -1.0% | +1.0% | +0.1% | +2.5% |
| Feb 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.68 | $19.11 | +2.3% | -2.6% | +0.1% | -3.0% | -1.0% | +1.0% |
| Feb 23 | BTIG | Maintains | Buy → Buy | — | $18.77 | $18.77 | +0.0% | -0.5% | -2.6% | +0.1% | -3.0% | -1.0% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $18.77 | $18.77 | +0.0% | -0.5% | -2.6% | +0.1% | -3.0% | -1.0% |
| Feb 20 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $18.17 | $17.98 | -1.0% | +3.3% | -0.5% | -2.6% | +0.1% | -3.0% |
| Feb 9 | BTIG | Maintains | Buy → Buy | — | $15.51 | $15.50 | -0.1% | +1.5% | -0.8% | +1.1% | -1.1% | +1.0% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.79 | $15.90 | +0.7% | -2.7% | -2.2% | -1.7% | +5.0% | +1.5% |
| Jan 15 | Goldman Sachs | Downgrade | Neutral → Sell | — | $17.41 | $16.48 | -5.3% | -6.1% | +2.5% | -2.6% | +2.3% | -6.5% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.34 | $15.17 | +5.8% | +28.9% | -2.2% | -5.5% | +1.8% | -6.1% |
| Jan 9 | BTIG | Upgrade | Neutral → Buy | — | $14.34 | $15.17 | +5.8% | +28.9% | -2.2% | -5.5% | +1.8% | -6.1% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $13.00 | +0.0% | -2.5% | +3.8% | +3.5% | +1.4% | -0.5% |
| Nov 3 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $10.10 | $10.33 | +2.3% | +1.0% | -0.7% | +4.5% | -2.8% | +3.3% |
| Oct 29 | Citigroup | Downgrade | Neutral → Sell | — | $9.82 | $9.46 | -3.7% | -2.1% | +2.1% | +3.0% | +1.0% | -0.7% |
| Oct 2 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.06 | $6.88 | -2.5% | +5.7% | +13.0% | +2.7% | +7.2% | -1.9% |
| Sep 30 | Citigroup | Downgrade | Buy → Neutral | — | $6.25 | $6.41 | +2.6% | +14.7% | -1.5% | +5.7% | +13.0% | +2.7% |
| Sep 30 | Guggenheim | Maintains | Buy → Buy | — | $6.25 | $6.41 | +2.6% | +14.7% | -1.5% | +5.7% | +13.0% | +2.7% |
| Sep 30 | Needham | Maintains | Buy → Buy | — | $6.25 | $6.41 | +2.6% | +14.7% | -1.5% | +5.7% | +13.0% | +2.7% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $6.25 | $6.41 | +2.6% | +14.7% | -1.5% | +5.7% | +13.0% | +2.7% |
| Sep 29 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $61.99 | $6.98 | -88.7% | -89.9% | +14.7% | -1.5% | +5.7% | +13.0% |
| Sep 29 | BTIG | Downgrade | Buy → Neutral | — | $61.99 | $6.98 | -88.7% | -89.9% | +14.7% | -1.5% | +5.7% | +13.0% |
| Aug 6 | Goldman Sachs | Maintains | Buy → Buy | — | $53.41 | $53.31 | -0.2% | -1.2% | -1.6% | +1.0% | +1.9% | +2.7% |
| Jun 3 | RBC Capital | Maintains | Outperform → Outperform | — | $41.16 | $47.82 | +16.2% | +18.0% | +5.1% | -4.3% | -4.0% | -0.6% |
| May 19 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $37.62 | $38.85 | +3.3% | +4.2% | +2.8% | -4.3% | -0.1% | +1.1% |
| May 13 | Needham | Maintains | Buy → Buy | — | $40.18 | $40.58 | +1.0% | -4.1% | -4.0% | +1.8% | -0.1% | +4.2% |
| Apr 30 | Needham | Maintains | Buy → Buy | — | $40.18 | $40.26 | +0.2% | +4.7% | -1.5% | +2.1% | -1.0% | -6.3% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.37 | $41.93 | -1.0% | -1.4% | -0.0% | -4.9% | +1.5% | -0.8% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $42.37 | $41.93 | -1.0% | -1.4% | -0.0% | -4.9% | +1.5% | -0.8% |
| Feb 27 | Goldman Sachs | Maintains | Buy → Buy | — | $42.37 | $41.93 | -1.0% | -1.4% | -0.0% | -4.9% | +1.5% | -0.8% |
| Jan 17 | Goldman Sachs | Upgrade | Neutral → Buy | — | $41.47 | $44.83 | +8.1% | +5.6% | +4.6% | +2.8% | -0.5% | -2.5% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.17 | $48.00 | -0.4% | -3.8% | -2.3% | +2.7% | -5.4% | -5.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.06 | $50.63 | -0.8% | +2.8% | -7.0% | -0.6% | +1.6% | +1.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.67 | $50.46 | -0.4% | +2.2% | +4.1% | -3.7% | -1.6% | +2.8% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.90 | $49.12 | +0.4% | -1.8% | +2.3% | -2.1% | +1.8% | +0.2% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $46.42 | $47.00 | +1.2% | +10.0% | +0.2% | -2.3% | +2.0% | +4.2% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.42 | $47.00 | +1.2% | +10.0% | +0.2% | -2.3% | +2.0% | +4.2% |
| Aug 26 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $49.77 | $48.32 | -2.9% | -3.2% | -2.6% | -0.2% | +1.4% | -1.5% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $43.06 | $43.23 | +0.4% | +6.9% | -3.9% | +2.4% | +0.0% | +3.7% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.97 | $43.68 | -0.7% | -4.9% | -3.9% | +5.1% | -0.4% | +3.5% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.96 | $41.36 | -1.4% | +3.5% | -0.3% | -1.4% | -3.0% | -3.0% |
| Jun 10 | Needham | Maintains | Buy → Buy | — | $41.67 | $41.37 | -0.7% | +0.7% | +3.5% | -0.3% | -1.4% | -3.0% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.86 | $40.84 | -0.0% | -2.7% | -2.7% | +1.0% | +2.3% | +0.1% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.66 | $43.95 | +0.7% | -2.4% | -1.5% | -2.5% | +1.9% | -2.3% |
| May 8 | Needham | Maintains | Buy → Buy | — | $43.66 | $43.95 | +0.7% | -2.4% | -1.5% | -2.5% | +1.9% | -2.3% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.02 | $41.48 | +1.1% | +5.4% | -1.9% | -0.4% | +0.6% | -1.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Bodenstedt MatthiasOff | Chief Financial Officer | Sell | 2,794 | $19.60 | $55K | 1,154,555 | +15.36% | — |
| Jun 17, 2026 | Bodenstedt MatthiasOff | Chief Financial Officer | Sell | 15,082 | $19.68 | $297K | 1,157,349 | +15.36% | — |
| Jun 17, 2026 | Reich KristianOff | Chief Scientific Officer | Sell | 50,000 | $19.43 | $972K | 2,824,551 | +0.10% | — |
| Jun 16, 2026 | Reich KristianOff | Chief Scientific Officer | Sell | 50,000 | $18.70 | $935K | 2,874,551 | +0.10% | — |
| Jun 15, 2026 | Reich KristianOff | Chief Scientific Officer | Sell | 50,000 | $18.89 | $944K | 2,924,551 | +0.10% | — |
| May 11, 2026 | Bodenstedt MatthiasOff | Chief Financial Officer | Sell | 13,653 | $20.02 | $273K | 1,172,431 | -0.11% | +4.15% |
8-K · 8.01
!! High
MoonLake Immunotherapeutics -- 8-K 8.01: Material Event / Announcement
MoonLake Immunotherapeutics' SLK demonstrated sustained efficacy in Phase 3 VELA trials for hidradenitis suppurativa, with 67.2% of patients achieving HiSCR75 response at Week 52, supporting potential regulatory approval and commercialization pathway.
Jun 22
8-K · 5.02
!!! Very High
MoonLake Immunotherapeutics -- 8-K 5.02: Executive Change
Jun 9
8-K
MoonLake Immunotherapeutics -- 8-K Filing
MoonLake Immunotherapeutics' manufacturing agreement with Vetter allows either party to terminate for uncured material breaches after 60 days' notice or without cause with 12 months' notice once all product schedules expire.
Jun 1
8-K · 2.02
!! High
MoonLake Immunotherapeutics -- 8-K 2.02: Earnings Results
May 11
8-K · 5.02
!!! Very High
MoonLake Immunotherapeutics Class A -- 8-K 5.02: Executive Change
MoonLake Immunotherapeutics (MLTX) appointed an interim chair and two new independent directors while Simon Sturge resigned, signaling potential governance restructuring that investors should monitor for strategic implications.
Feb 23
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 3,451,628 | $64M | New | Mar 2026 |
| 2 | D.e. Shaw & Co | 2,390,661 | $45M | Reduced | Mar 2026 |
| 3 | Mpm Bioimpact Llc | 1,811,082 | $34M | New | Mar 2026 |
| 4 | Morgan Stanley | 2,089,162 | $28M | Added | Dec 2025 |
| 5 | Point72 Asset Management | 1,368,518 | $26M | Added | Mar 2026 |
| 6 | Citadel Advisors Llc | 1,323,728 | $25M | Added | Mar 2026 |
| 7 | Jane Street Group, Llc | 1,682,148 | $22M | Added | Dec 2025 |
| 8 | Two Sigma Investments, Lp | 1,122,312 | $21M | Added | Mar 2026 |
| 9 | Vivo Capital, Llc | 1,000,000 | $19M | New | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 1,088,514 | $18M | Added | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 724,794 | $14M | Added | Mar 2026 |
| 12 | Walleye Capital Llc | 640,944 | $12M | Added | Mar 2026 |
| 13 | Millennium Management | 576,092 | $11M | Reduced | Mar 2026 |
| 14 | Hrt Financial Lp | 487,583 | $9M | Reduced | Mar 2026 |
| 15 | Adar1 Capital Management, Llc | 457,137 | $9M | New | Mar 2026 |
| 16 | Longaeva Partners L.p. | 410,000 | $8M | New | Mar 2026 |
| 17 | Susquehanna International Group, Llp | 341,424 | $6M | Reduced | Mar 2026 |
| 18 | Renaissance Technologies Llc | 276,772 | $5M | Added | Mar 2026 |
| 19 | Bnp Paribas Financial Markets | 239,838 | $4M | Added | Mar 2026 |
| 20 | Rhenman & Partners Asset Management Ab | 239,500 | $4M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 18
All ↗
Valuation
Market Cap
$1.43B
Enterprise Value
$1.11B
P/E (TTM)
-5.71x
Forward P/E
—
PEG Ratio
-0.04x
P/B
4.69x
P/S
—
P/FCF
-7.29x
EV/EBITDA
—
Shares Out
64.5M
Financials (TTM)
Revenue
$0
Net Income
-$257.1M
EBITDA
-$245.8M
Free Cash Flow
-$196.0M
Op Cash Flow
-$196.0M
EPS Basic
$-3.53
EPS Diluted
$-3.88
EPS Forward
$-3.62
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$424.4M
Total Liab.
$120.0M
Total Equity
$304.5M
Cash
$394.0M
LT Debt
$74.5M
Book Value/Sh
$4.72
Debt/Equity
0.25x
Current Ratio
9.27
Quick Ratio
9.27
Returns & Growth
ROE
-74.7%
ROA
-53.6%
ROIC
-64.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
-86.8%
Price Returns
2W
+4.3%
1M
+17.1%
3M
+9.5%
6M
+39.7%
12M
-50.8%
Technicals
52W High
$61.99
52W Low
$6.25
50d MA
$17.95
200d MA
$18.63
RSI (14)
70.10
ATR (14)
$1.12
Beta
1.19
Avg Volume
996K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$25.25
High
$35.00
Low
$10.00
Median
$28.00
Data updated apr 26, 2026 12:38pm
· Source: financialmodelingprep.com